S epsis, the systemic inflammatory response to infection, is a multisystem disorder (1) . When pathogens invade the hosts, inflammatory defense mechanisms are activated resulting in immune, hormonal, metabolic, bioenergetic, and autonomic nervous system modifications. The time-dependent interplay between these systems ideally eradicates the invading organisms, but can also result in multiple organ dysfunction (2) . Cardiac depression with impaired left ventricular ejection fraction is a well-described manifestation of this syndrome and can be diagnosed in up to 60% of patients with septic shock (3) . However, sepsis-induced myocardial depression can be viewed as adaptive and, at least partially, protective process. The objectives of this article are 1) to discuss therapeutic measures with cardioprotective properties; and 2) to review studies on ␤-blocker therapy during sepsis.
Sepsis-induced cardiac depression
Early sepsis is characterized by elevated catecholamine levels (4 -6), which derive from the autonomous nervous system, the gut (7), lymphocytes (8, 9) , macrophages (10) , and neutrophils (11, 12) . This adrenergic response augments cardiac contractility (13) and heart rate (14) , hence increasing cardiac energy demands. As sepsis progresses, circulatory derangements and mitochondrial dysfunction lead to tissue hypoxia and dysoxia, respectively. On a subcellular level, this reduces adenosine-5Ј-triphosphate formation and energy supply (15) . When energy demand outstrips supply, the cardiac myocytes are at risk of cell death. Elevated troponin levels are indicative for such injury (16, 17) . To prevent further damage, the cells have to reduce their energy requirements. It can be hypothesized that they do so by reducing their cell-specific functions, hence creating a new balance between energy production and demand (Fig. 1) . Several underlying mechanisms of sepsis-induced myocardial depression have been identified (18) . Of major importance is the attenuation of the adrenergic response at the cardiomyocyte level resulting from downregulation of ␤-adrenergic receptors (19, 20) and depression of postreceptor signaling pathways (21) (22) (23) (24) . These changes are mediated by cytokines from activated immune cells (25, 26) . Clinically, this adrenergic downregulation leads to a reversible hyporesponsiveness to dobutamine in patients with septic shock for up to 10 days (27) . These effects are probably enhanced by neuronal apoptosis in the cardiovascular autonomic centers (28) and by inactivation of catecholamines through reactive oxygen species (29) . Although the overall cardiac function is markedly reduced, the cardiomyocytes survive in a hibernation-like state. Once the septic insult is overcome and cellular energy supply reestablished, the cardiomyocytes start contracting again. Clinicians will note a normalization of the cardiac function in sepsis survivors, typically occurring between days 7 and 10 (30).
␤-Blockers for the septic heart
In view of these adaptive and protective mechanisms, current treatment guidelines must be challenged and new algorithms proposed. With the Hippocratic Oath "keep the sick from harm" in mind, external cardiac stimulation with ␤-1 agonists might be inappropriate in established organ dysfunction (31) . Indeed, efforts to enhance oxygen delivery above supranormal values by dobutamine administration showed no benefit and even harm during established sepsis with concurrent organ failure (32, 33 Objectives: Cardiac depression is a well-described manifestation of the sepsis syndrome. An important underlying mechanism is the attenuation of the adrenergic response at the cardiomyocyte level. By reducing their cell-specific function (contractility), the cardiomyocytes reduce their energy expenditure. Consequently, the cardiac myocytes survive in a hibernation-like state as long as intracellular energy generation is limited. The objective of this study was to review ␤-blocker therapy for the treatment of septic patients.
Data Source: MEDLINE database. Data Synthesis: During established sepsis with organ failure, external adrenergic stimulation of the heart must be kept at a minimum. To blunt the adrenergic response, ␤-blockers have been used in several preclinical and clinical studies. In septic animals, ␤-blockers reduced heart rate, whereas stroke volume was maintained. Esmolol in vivo prevented the downregulation of adrenergic pathways, preserving full cardiac function ex vivo. In addition, ␤-blockers reduced the inflammatory response and the degree of lung injury. Some animal studies documented survival benefits, particularly when ␤-blockers were administered before the septic insult. In patients with septic shock, blood pressure increased and cardiac indices remained stable with metoprolol administration.
Conclusions KEY WORDS: sepsis; shock; heart failure; cardiomyopathy; ␤-blocker; adrenergic blockade; metoprolol; esmolol; multiple organ failure quate analgesia and sedation as well as avoidance of exogenous stress keep adrenergic stimulation of the heart at a minimum (34) . However, some authors pushed it further and tested the use of ␤-blockers in preclinical and clinical studies (Table 1) .
␤-Blockers in Animal Models of Sepsis. Using an endotoxin model in dogs, Berk et al (35) assessed the effects of the nonselective ␤-blocker propranolol. The ␤-blocker significantly improved survival, even when it was started 60 mins after lipopolysaccharide injection. Propranolol also prevented the second phase of hypotension, hence reducing fluid requirements. Arterial PO 2 values were better in propranolol-treated animals, and postmortem investigations showed less lung injury in these animals. In contrast, Schmitz et al (36) demonstrated a negative effect on outcome in propranololtreated mice undergoing cecal ligation and puncture. In this study, ␤-blocker treatment was started at the time of surgery, potentially impairing the initial resuscitation phase. Another explanation for the negative result is that nonselective ␤-blockers inhibit the activation of ␤-2 receptors, which have cardioprotective properties (37).
Suzuki and coworkers (38) infused the ␤-1 selective adrenergic blocker esmolol into septic rats, which reduced heart rates, blood pressures, and tumor necrosis factor-␣ plasma levels. Interestingly, lactate levels did not increase compared with controls, indicating no excessive anaerobic metabolism. Twenty-four hours later, hearts were removed and mounted on an isolated perfused heart preparation. Hearts from ␤-blocker-treated animals developed higher stroke volumes and used oxygen more efficiently. In separate immunohistochemistry experiments, the authors showed a significant reduction of the ␤-1 receptor density in septic animals. ␤-blocker treatment blunted this response and increased the number of receptors. It can be concluded that ␤-blockers in vivo prevented the downregulation of adrenergic pathways, preserving full cardiac function ex vivo where the circulating catecholamines and ␤-blockers were excluded from the perfusion medium.
Hagiwara and coworkers (39) administered a 24-hr infusion of landiolol, a highly selective ␤-1 adrenergic receptor antagonist with a very short half-life, to lipopolysaccharide-treated rats. landiolol blunted the increases of tumor necrosis factor-␣, interleukin-6, and high-mobility group box 1 plasma levels. Assessing the heart ex vivo using the Langendorff technique, the hearts from landiololtreated animals showed better systolic and diastolic performance. Postmortem analysis of the lungs showed less tissue injury with landiolol.
Ackland et al (40) investigated the effects of the ␤-1 antagonist metoprolol in a different rodent model of sepsis. The systemic administration of metoprolol improved survival significantly only when the drug was given before the endotoxin injection. The intracerebral administration of metoprolol failed to improve survival, suggesting that peripheral mechanisms are important for attenuating lipopolysaccharide-induced inflammation. In separate experiments using a fluid-resuscitated, long-term model of fecal peritonitis, metoprolol significantly reduced heart rate but not stroke volume. There was a trend for improved survival when metoprolol was continuously infused intravenously after the initial fluid resuscitation phase.
␤-Blockers in Septic Patients. Berk and colleagues (41) treated five septic patients with propranolol infusions. These patients had prolonged and therapy-refractory shock before ␤-blocker treatment was started. Two patients died, but the other three patients showed an increase in blood pressure and recovered. The results of this study are difficult to translate to current practice, because several antiquated sepsis therapies (glucagons, high-doses steroids, digitalis) were used. In addition, neither noradrenaline nor adrenaline was available at that time.
Gore and Wolfe (42) treated six normotensive septic patients with a 3-hr infusion of esmolol, a short-acting ␤-1 antagonist. The dose was chosen to reduce the heart rate by 20%, which decreased cardiac output accordingly. Importantly, this did not limit oxygen use, affect whole body energy expenditure, or alter adenosine-5Ј-triphosphate availability.
Schmittinger and colleagues (43) treated patients with septic shock with fluids, noradrenaline, milrinone, and vasopressin. Metoprolol through an enteral route was added within 48 hrs after the onset of shock. Heart rate targets between 65 and 95 beats/min were achieved in 39 of 40 patients. Stroke volumes increased and cardiac indices remained stable in the study population. Overall, mean arterial blood pressures increased and noradrenaline and milrinone requirements decreased. However, noradrenaline and milrinone doses had to be increased in 22.5% and 15% of the patients, respectively.
An overview of studies with ␤-blocker treatments in septic patients is given in Table 1 . Apart from their action on the cardiovascular system, ␤-blockers have other profound effects during sepsis (44 -46) . Inflammation, metabolism, and coagulation are all influenced by ␤-adrenergic modulation. Of note, ␤-blockers have also been successfully used in critically ill patients with myocarditis (47), tako-tsubo cardiomyopathy (48, 49) , head injury (50), and burns (51, 52) .
Other (experimental) forms of cardioprotection during sepsis
Cardiac afterload must be kept at a minimum. The current recommendation of a mean arterial blood pressure Ն65 mm Hg (53) is likely to result in a critical high afterload for the dysfunctional left ventricle and should be reconsidered in future studies. Similarly, right ventricular afterload can be minimized using ventilator settings with low plateau pressures (54) . Levosimendan, a calcium sensitizer, might be a valuable alternative for the ␤-1 agonists, particularly in patients treated with ␤-blockers. It has been successfully used in animal models of sepsis (55) (56) (57) and septic patients (58) . Its main limitations are the vasodilating properties, which potentially decrease the already low blood pressure. Next, isolated heart rate reduction has the potential to considerably lower cardiac energy demands. In addition, a lower heart rate will allow for better ventricular filling during diastole, hence improving stroke volume. ATP, adenosine-5Ј-triphosphate; BP, blood pressure; CI, cardiac index; CO cardiac output; CRP, C-reactive protein; HMGB, high-mobility group box; HR, heart rate; IL, interleukin; LPS, lipopolysaccharide; LVEDP, left ventricular end diastolic pressure; MCP, monocyte chemotactic protein; NA, noradrenaline; NF, nuclear factor; SAPS, Simplified Acute Physiologic Scale; ScvO 2 , central-venous oxygen saturation; SV, stroke volume; TNF, tumor necrosis factor.
The novel I f -channel inhibitor lvabradine leads to a heart rate-dependent heart rate reduction, and first clinical studies in acute patients with heart failure are promising (59) . When cardiac output is not supported or even therapeutically reduced to protect the heart, new devices or biomarkers are needed to monitor the perfusion and metabolism of vital organs (brain, heart, kidney, gut, liver). To reduce systemic cellular energy requirements, mild therapeutic hypothermia might be applied (60) . Ultimately, if cardiac output falls below a critical threshold, mechanical assist devices could provide bridging to recovery (61) .
Roundtable discussion
The topic was discussed at the Roundtable conference "Thinking Outside the Box" before the 30th International Symposium on Intensive Care and Emergency Medicine (March 9 -12, 2010) in Brussels, Belgium. Decatecholaminization, which is the reduction of endogenous and exogenous adrenergic stimulation, was agreed to be important in the management of the critically ill patient, particularly in the transition between acute and chronic critical illness. ␤-blocker treatment was considered an interesting option in this respect. However, excessive ␤-blocker dosing may have negative inotropic effects and cause pump failure in an already depressed heart, leading to inappropriately low cardiac output and pulmonary congestion. Hence, ␤-blockers should be titrated in septic patients, and close hemodynamic monitoring is warranted for early detection of potential negative effects. Others commented on the ongoing debate on perioperative ␤-blocker treatment (62) . Recently, the American College of Cardiology Foundation and the American Heart Association limited the indication for perioperative ␤-blocker therapy to patients already receiving ␤-blockers (63) . Similarly, ␤-blockers in sepsis could be studied first in patients with pre-existing ␤-blocker therapy. Another patient group worth investigating is patients with elevated troponin levels indicative for acute cardiac injury.
Conclusions
Preclinical and clinical studies with ␤-blockers during sepsis show promising results. ␤-1 receptor blockade seems superior to nonselective ␤-blockade, because ␤-2 receptor activation has cardioprotective properties. ␤-blocker treatment ideally starts before the septic insult or after hemodynamic stabilization. Finally, all novel concepts discussed in this article necessitate rigorous testing before they can be implemented in clinical practice. Studies should first investigate patients with preexisting ␤-blocker treatment and/or evidence of acute cardiac injury. Thereby, ␤-blocker titration and close attention to hemodynamic parameters should be applied. However, if the concept of ␤-blocker therapy in sepsis proves successful, it might be usefully extended to other stress cardiomyopathies commonly encountered in the critically ill.
